Guggenheim reiterates this biotech stock as a top pick
Celldex Therapeutics Targets 2027 Filing for Barzolvolimab After Phase 3 Results
Canaccord Genuity Maintains Buy on Celldex Therapeutics, Raises Price Target to $68
Morgan Stanley Maintains Overweight on Celldex Therapeutics, Raises Price Target to $61
Celldex Stock In Focus After Earnings Loss And Shelf Filing
Celldex: Q3 Earnings Snapshot
Celldex Reports Third Quarter Financial Results and Provides Corporate Update
Celldex Therapeutics Announces Filing Of Mixed Shelf Offering, Size Undisclosed
Celldex Therapeutics Q3 EPS $(0.96) Beats $(1.02) Estimate
Celldex to Present at Upcoming Investor Conferences
Celldex Therapeutics (CLDX) Stock Looks Rich After Shareholder Investigation
Celldex Therapeutics: Trying To Put Its Troubled History Behind It
HC Wainwright & Co. Reiterates Buy on Celldex Therapeutics, Maintains $64 Price Target
Can Celldex (CLDX) Overcome Its Heavy Burn Rate for Long-Term Success?
Leerink Partners Maintains Outperform on Celldex Therapeutics, Raises Price Target to $88
Morgan Stanley Maintains Overweight on Celldex Therapeutics, Raises Price Target to $57
CLDX Stock Slumps 11% – This Analyst Sees Nearly 90% Upside, Calls Phase 3 Trial Safety Concerns ‘Misplaced’
Celldex Phase III CSU Trials Hit Endpoints as Barzolvolimab Shows Durable Responses
Celldex Therapeutics, Inc. (CLDX) Discusses Positive Phase 3 Results for Barzolvolimab in Chronic Spontaneous Urticaria Transcript
Celldex Therapeutics, Inc. (CLDX) Discusses Positive Phase 3 Results for Barzolvolimab in Chronic Spontaneous Urticaria - Slideshow
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.